The litigation covers investors who acquired Insulet securities between February 21, 2025, and May 26, 2026. According to the filing, the company allegedly maintained defective manufacturing controls, creating risks that its products—including the Omnipod 5 and Omnipod Dash systems—could violate safety regulations or cause patient harm. These internal failures were not disclosed to shareholders, rendering public statements during the period materially misleading.

The market reacted sharply to disclosures regarding these issues. On March 12, 2026, the company announced a voluntary correction for specific Omnipod 5 lots, causing the stock price to drop 6.88%. A subsequent announcement on May 26, 2026, concerning potential insulin under-delivery across multiple product lines, triggered a further decline of 5.07%. Investors seeking to serve as lead plaintiff must petition the court by August 31, 2026. Pomerantz LLP is representing the class, citing violations of the Securities Exchange Act of 1934.